Lexeo Reports Interim PKP2 Gene Therapy Data

Lexeo reported interim single-arm Phase 1/2 LX2020 data in PKP2 arrhythmogenic cardiomyopathy. Seven high-dose participants had an 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest…





